Philippe Chahinian, MD


  • 30 years in academic oncology.
  • 9 years in pharma industry as a medical executive.
  • US Board-Certified in Internal Medicine and Oncology.

CMO; Medical Monitoring; Phase 1-3 Clinical Trials; Medical Expertise for Study Feasibility, Design, Site, Conduct, Analysis, Reporting, Databases, and Efficacy/Safety; Regulatory Submissions; RFPs and RFIs; Business Development; Pharma Scientific Presentations; Internal Training/Teaching; Medical Specialties: Oncology, Hematology, Internal Medicine.
MD from University Rene Descartes in Paris, France. Former member of EORTC (The European Organisation for Research and Treatment of Cancer) and founder of Measurable Tumors Group, former member and chair of the Respiratory Committee of CALGB (The Cancer and Leukemia Group B), and former member of International Association for the Study of Lung Cancer. Awarded a US National Cancer Institute grant to study experimental chemotherapy of human mesothelioma xenografts in athymic mice, and chaired the first randomized trial of mesothelioma in CALGB
Author or co-author of more than 100 peer-reviewed medical articles and 40 medical textbook chapters.
Fluent in English and French.
Executive Medical Director – Oncology, InVentiv Health Clinical
CRO medical director involved in all aspects of corporate medical activities. Participated in a large number of new RFPs/RFIs, performed medical monitoring for clinical trials, and engaged in business development.
Medical Director – Oncology, PRA International
Provided medical expertise for study feasibility, study design, conduct, analysis and reporting, generation of integrated databases, site identification, pooled analyses for efficacy and safety, study monitoring, and dossiers for regulatory submissions for market authorizations of new medicinal products, and diagnostics and devices. Assisted Business Development group in marketing and selling company services, participated in external scientific presentations sponsored by PRA, supported internal teaching activities for the PRA Therapeutic Expertise group as well as in CRA training sessions.
Professor of Medicine, Division of Medical Oncology, Mount Sinai School of Medicine
Attending Physician, Division of Medical Oncology, Mount Sinai School of Medicine
Chief, Division of Medical Oncology and Director of the Cancer Center, St. Luke’s / Roosevelt Hospital Center
Associate Professor, Department of Neoplastic Diseases, Mount Sinai School of Medicine

Subscribe and Follow

Have the latest akta Pharmaceutical Development news delivered right to your inbox. 
And we will never share your information.